#Securities Class Action #EBITDA guidance #Chemours Company

Investors Alert: Key Deadline Approaches for Chemours Lawsuit

As we near the end of 2026, investors in The Chemours Company (NYSE: CC) are being alerted to a pivotal deadline concerning a securities class action lawsuit. The suit addresses allegations of misleading financial information regarding the company's projected EBITDA guidance for the year. With the deadline for investors to apply for lead plaintiff status set for December 7, 2026, it is essential for affected shareholders to understand the details surrounding this case.

Background of the Case

The lawsuit revolves around claims that Chemours did not accurately represent its financial forecasts for 2026, particularly concerning its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). The allegations suggest that the specialty chemicals company made assertions regarding its full-year outlook, which ultimately proved to be unfounded. Investors are advised to scrutinize the company's guidance, which saw a reduction from an expected $800 million to $900 million down to a more tempered $775 million to $825 million.

The significant decline of 18.63% in CC's share price following this announcement underscores the impact of these revelations on investor confidence. As Joseph E. Levi, Esq., the attorney involved in this case, noted, “Investors deserve transparency regarding the material risks that could affect their investments.” Highlighting the need for openness, the complaint raises concerns about whether the reported forecast genuinely considered the sales dynamics emerging from 2025.

Allegations of Prebuy Activity

A crucial element of the case involves claims that Chemours’ guidance neglected to account for substantial pre-buying activity in the North American aftermarket for its Opteon refrigerants. The specialty chemicals market had already begun stocking these products in 2025, leading to the assertion that a significant portion of the sales anticipated for 2026 had already been realized in the previous year.

Management's confidence—expressed during a February 2026 earnings call—seemed misplaced as analysts queried the feasibility of achieving expected earnings growth. Despite being reassured that management had